Contact Us
Drug Search Results
More Filters [+]

Abicipar pegol

Alternative Names: abicipar pegol, agn-150998, mp0112
Latest Update: 2023-07-01
Latest Update Note: PubMed Publication

Product Description

Abicipar Pegol is an anti-VEGF molecule based on the designed ankyrin repeat proteins (DARPin) therapeutics (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182559/)

Mechanisms of Action: VEGF Inhibitor

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Abicipar pegol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Macular Degeneration|Neovascular age-related macular degeneration

Phase 2: Macular Degeneration|Macular Edema

Phase 1: Wet Macular Degeneration|Macular Edema|Macular Degeneration

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CEDAR

P3

Completed

Neovascular age-related macular degeneration

2019-04-16

SEQUOIA

P3

Completed

Neovascular age-related macular degeneration

2019-04-03

NCT03539549

P2

Completed

Macular Degeneration

2019-02-27

PINE

P1

Completed

Macular Degeneration

2018-10-08

22%

Recent News Events

Date

Type

Title

07/01/2023

PubMed

 Differential diagnosis of endophthalmitis after intravitreal drug injection for age related macular degeneration: sterile vs. infectious.

05/11/2023

PubMed

 Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results.

01/01/2023

PubMed

 [Modern trends in anti-VEGF therapy for age-related macular degeneration].

08/09/2021

News Article

 Molecular Partners to Regain Global Rights to Abicipar

04/27/2021

News Article

 Allergan, an AbbVie Company, to Share New Data Highlighting Latest Advancements in Eye Care at ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting

04/19/2021

News Article

 The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc.

03/17/2021

News Article

 Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions